# GLB1

## Overview
The GLB1 gene encodes the enzyme beta-galactosidase, a lysosomal hydrolase critical for the degradation of complex carbohydrates such as GM1 gangliosides, glycosaminoglycans, and glycopeptides. This enzyme is essential for cellular metabolism, as it facilitates the breakdown of these molecules into simpler forms that can be utilized or excreted by the cell (Morrone2000?galactosidase). The GLB1 gene also gives rise to an alternatively spliced variant known as the elastin binding protein (EBP), which, although lacking enzymatic activity, plays a significant role in the assembly of elastic fibers on the cell surface (Caciotti2005Role). Mutations in the GLB1 gene are linked to lysosomal storage disorders such as GM1 gangliosidosis and Morquio B disease, which are characterized by the accumulation of undegraded substrates due to deficient enzyme activity (Caciotti2011GM1; Cho2021GLB1related). The study of GLB1 and its encoded proteins is crucial for understanding the molecular basis of these disorders and developing potential therapeutic strategies.

## Structure
The GLB1 gene encodes the human β-galactosidase enzyme, which is a lysosomal enzyme involved in the breakdown of glycosaminoglycans. The primary structure of the GLB1 protein consists of 677 amino acids (Priyanka2021A). The secondary structure includes elements such as alpha helices and beta sheets, although specific details are not provided in the context. The tertiary structure of GLB1 has been partially resolved, with a 3D structure available for amino acids 24-677, indicating the overall folding of the protein (Priyanka2021A). The quaternary structure of GLB1 is a dimeric form, composed of two identical subunits, known as a Homo 2-mer (Priyanka2021A).

The GLB1 protein contains specific domains, including a galactose-binding domain, which is crucial for its enzymatic activity. Post-translational modifications such as glycosylation are significant for the protein's function, as the precursor protein is modified into a glycosylated form of 85kDa before being processed into a 64kDa mature enzyme in lysosomes (Morrone2000?galactosidase). The GLB1 gene also produces two alternatively spliced mRNAs, one encoding the lysosomal enzyme and another encoding the elastin binding protein (EBP), which has no enzymatic activity and a different subcellular localization (Caciotti2011GM1; Morrone2000?galactosidase).

## Function
The GLB1 gene encodes the enzyme beta-galactosidase, which plays a crucial role in the lysosomal degradation of GM1 gangliosides, glycosaminoglycans, and glycopeptides. This enzyme is part of a lysosomal complex that includes protective protein cathepsin A (PPCA) and neuraminidase (NEU1), which are essential for the intracellular transport and stability of beta-galactosidase and neuraminidase (Morrone2000?galactosidase). In healthy human cells, beta-galactosidase hydrolyzes terminal beta-galactosidic residues, contributing to the breakdown of complex molecules into simpler ones that can be utilized or excreted by the cell (Morrone2000?galactosidase).

The GLB1 gene also produces an alternatively spliced variant known as the elastin binding protein (EBP), which is involved in the assembly of elastic fibers on the cell surface. EBP functions as a molecular chaperone, facilitating the secretion and assembly of tropoelastin into elastic fibers, and is part of a cell surface receptor complex (Caciotti2005Role; Morrone2000?galactosidase). This protein interacts with elastin-derived peptides, influencing endothelial cell migration and gene expression, which is significant in processes like angiogenesis (Skeie2012Molecular).

## Clinical Significance
Mutations in the GLB1 gene are associated with two primary lysosomal storage disorders: GM1 gangliosidosis and Morquio B disease. GM1 gangliosidosis is a neurodegenerative disorder characterized by the accumulation of GM1 ganglioside in neuronal tissue, leading to symptoms such as psychomotor regression, visceromegaly, and skeletal abnormalities. It is classified into three clinical forms based on age of onset: infantile, juvenile, and adult, with the infantile form being the most severe (Caciotti2011GM1; Morrone2000?galactosidase). 

Morquio B disease, also known as mucopolysaccharidosis IVB, is marked by skeletal dysplasia without central nervous system involvement. It results from the accumulation of keratan sulfate due to deficient beta-galactosidase activity (Yuskiv2020Morquio; Cho2021GLB1related). 

The clinical manifestations of these disorders depend on the specific mutations in the GLB1 gene, which can affect enzyme stability or the active site, influencing the degradation of substrates like GM1 ganglioside and keratan sulfate (Yuskiv2020Morquio; Kwak2015Biochemical). Over 130 mutations in the GLB1 gene have been identified, contributing to the phenotypic variability observed in affected individuals (Caciotti2011GM1).

## Interactions
The GLB1 gene encodes the enzyme beta-galactosidase, which is involved in several protein interactions, particularly within lysosomal and non-lysosomal complexes. In lysosomes, GLB1 forms a multienzyme complex with protective protein cathepsin A (PPCA), neuraminidase (NEU1), and galactosamine 6-sulphate sulfatase (GALNS). This complex is crucial for the stability and function of the enzyme, with PPCA acting as a protective protein for GLB1 (Caciotti2005Role). A smaller lysosomal complex containing only GLB1 and PPCA has also been described (Caciotti2005Role).

On the cell surface, the elastin-binding protein (EBP), derived from the same GLB1 gene, interacts with PPCA and NEU1, playing a role in the assembly of elastic fibers. EBP acts as a molecular chaperone, protecting tropoelastin from premature degradation and facilitating its assembly into a microfibrillar scaffold (Caciotti2005Primary). EBP contains a galactolectin domain that binds to microfibrillar acceptors in the glycosylated microfibrillar scaffold of elastic fibers (Caciotti2005Primary).

Mutations in the GLB1 gene can affect these interactions, leading to impaired elastogenesis and contributing to the pathology of GM1-gangliosidosis (Caciotti2005Role).


## References


[1. (Caciotti2011GM1) Anna Caciotti, Scott C. Garman, Yadilette Rivera-Colón, Elena Procopio, Serena Catarzi, Lorenzo Ferri, Carmen Guido, Paola Martelli, Rossella Parini, Daniela Antuzzi, Roberta Battini, Michela Sibilio, Alessandro Simonati, Elena Fontana, Alessandro Salviati, Gulcin Akinci, Cristina Cereda, Carlo Dionisi-Vici, Francesca Deodato, Adele d’Amico, Alessandra d’Azzo, Enrico Bertini, Mirella Filocamo, Maurizio Scarpa, Maja di Rocco, Cynthia J. Tifft, Federica Ciani, Serena Gasperini, Elisabetta Pasquini, Renzo Guerrini, Maria Alice Donati, and Amelia Morrone. Gm1 gangliosidosis and morquio b disease: an update on genetic alterations and clinical findings. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(7):782–790, July 2011. URL: http://dx.doi.org/10.1016/j.bbadis.2011.03.018, doi:10.1016/j.bbadis.2011.03.018. This article has 115 citations.](https://doi.org/10.1016/j.bbadis.2011.03.018)

[2. (Caciotti2005Primary) Anna Caciotti, Maria Alice Donati, Tiziana Bardelli, Alessandra d’Azzo, Graziella Massai, Luciana Luciani, Enrico Zammarchi, and Amelia Morrone. Primary and secondary elastin-binding protein defect leads to impaired elastogenesis in fibroblasts from gm1-gangliosidosis patients. The American Journal of Pathology, 167(6):1689–1698, December 2005. URL: http://dx.doi.org/10.1016/s0002-9440(10)61251-5, doi:10.1016/s0002-9440(10)61251-5. This article has 35 citations.](https://doi.org/10.1016/s0002-9440(10)61251-5)

[3. (Skeie2012Molecular) Jessica M. Skeie, Jasmine Hernandez, Aleksander Hinek, and Robert F. Mullins. Molecular responses of choroidal endothelial cells to elastin derived peptides through the elastin-binding protein (glb1). Matrix Biology, 31(2):113–119, March 2012. URL: http://dx.doi.org/10.1016/j.matbio.2011.11.003, doi:10.1016/j.matbio.2011.11.003. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2011.11.003)

[4. (Cho2021GLB1related) Sung Yoon Cho and Dong-Kyu Jin. Glb1-related disorders: gm1 gangliosidosis and morquio b disease. Journal of Genetic Medicine, 18(1):16–23, June 2021. URL: http://dx.doi.org/10.5734/jgm.2021.18.1.16, doi:10.5734/jgm.2021.18.1.16. This article has 5 citations.](https://doi.org/10.5734/jgm.2021.18.1.16)

[5. (Yuskiv2020Morquio) Nataliya Yuskiv, Katsumi Higaki, and Sylvia Stockler-Ipsiroglu. Morquio b disease. disease characteristics and treatment options of a distinct glb1-related dysostosis multiplex. International Journal of Molecular Sciences, 21(23):9121, November 2020. URL: http://dx.doi.org/10.3390/ijms21239121, doi:10.3390/ijms21239121. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21239121)

[6. (Morrone2000?galactosidase) A. Morrone, T. Bardelli, M.A. Donati, M. Giorgi, M. Di Rocco, R. Gatti, R. Parini, R. Ricci, G. Taddeucci, A. D’Azzo, and E. Zammarchi. ?-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in gm1-gangliosidosis patients with cardiac involvement. Human Mutation, 15(4):354–366, April 2000. URL: http://dx.doi.org/10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L, doi:10.1002/(sici)1098-1004(200004)15:4<354::aid-humu8>3.0.co;2-l. This article has 82 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/(SICI)1098-1004(200004)15:4)

[7. (Kwak2015Biochemical) Jae Eun Kwak, Mi-Young Son, Ye Seul Son, Myung Jin Son, and Yee Sook Cho. Biochemical and molecular characterization of novel mutations in glb1 and neu1 in patient cells with lysosomal storage disorders. Biochemical and Biophysical Research Communications, 457(4):554–560, February 2015. URL: http://dx.doi.org/10.1016/j.bbrc.2015.01.023, doi:10.1016/j.bbrc.2015.01.023. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2015.01.023)

[8. (Priyanka2021A) K. Priyanka, N. Madhana Priya, and R. Magesh. A computational approach to analyse the amino acid variants of glb1 protein causing gm1 gangliosidosis. Metabolic Brain Disease, 36(3):499–508, January 2021. URL: http://dx.doi.org/10.1007/s11011-020-00650-y, doi:10.1007/s11011-020-00650-y. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11011-020-00650-y)

[9. (Caciotti2005Role) Anna Caciotti, Maria Alice Donati, Avihu Boneh, Alessandra d’Azzo, Antonio Federico, Rossella Parini, Danielas Antuzzi, Tiziana Bardelli, Daniele Nosi, Virginia Kimonis, Enrico Zammarchi, and Amelia Morrone. Role of ?-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with gm1-gangliosidosis. Human Mutation, 25(3):285–292, 2005. URL: http://dx.doi.org/10.1002/humu.20147, doi:10.1002/humu.20147. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20147)